Francesca Barone
Chief Tech/Sci/R&D Officer en CANDEL THERAPEUTICS, INC. .
Fortuna: 294 918 $ al 31/03/2024
Perfil
Francesca Barone is currently the Chief Scientific Officer at Candel Therapeutics, Inc. She previously worked as the Director-laboratories at the Institute of Translational Medicine.
From 2010 to 2019, she was an Associate Professor at the University of Birmingham.
In 2019, she became the Head-Experimental Medicine at Senda Biosciences, Inc. Dr. Barone holds a doctorate degree from Sapienza University of Rome and King's College London.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 28/11/2023 | 186 657 ( 0.65% ) | 294 918 $ | 31/03/2024 |
Cargos activos de Francesca Barone
| Empresas | Cargo | Inicio |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
Antiguos cargos conocidos de Francesca Barone.
| Empresas | Cargo | Fin |
|---|---|---|
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/11/2020 |
| University of Birmingham | Corporate Officer/Principal | 01/05/2019 |
| Institute of Translational Medicine | Corporate Officer/Principal | - |
Formación de Francesca Barone.
| Sapienza University of Rome | Doctorate Degree |
| King's College London | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
| Institute of Translational Medicine |
- Bolsa de valores
- Insiders
- Francesca Barone
